Lupin Ltd. — Biomedical Watch V2

Traitements6programmes

Essais4liés

Publications6liées

SourceDBlocale

Traitements

6

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
MexiletineDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Myopathies, Sclérose latérale amyotrophique	Non applicable	Ralentissement de la progression	France	À vérifier
Track-DM — An Ambispective Natural History Study in Myotonic Dystrophy Patients Linking Retrospective Data Captured From the DM-Scope Registry With a Prospective 24-month Follow-upThis natural history observational study is being conducted to follow patients with DM1 or DM2 over a 2 year period to study the presence of myotonia, how it's perceived and its impact on patients quality of life. This study will be conducted at 6 study sites located in France.100 Patients will be recruited from the DM Scope Registry only. The study involves two parts. Part 1 will look back up to 18 months of past medical history that is already available from the DM Scope Registry. Part 2 will follow the same patients for 24 months, with study visits at Day 1 (Baseline), 12 months and 24 months. The goal is to better understand how myotonia symptoms and complications such as heart and other systemic problems develop and change over time. A smaller, sub-study will take place at one site, using new exploratory methods in about 40 patients with DM1 who are also part of the Track DM Study.	Myopathies	À vérifier	Traitement symptomatique	France	À vérifier
MexiletineDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	Phase 2	Ralentissement de la progression	United States	À vérifier
Track-DM — An Ambispective Natural History Study in Myotonic Dystrophy Patients Linking Retrospective Data Captured From the DM-Scope Registry With a Prospective 24-month Follow-upThis natural history observational study is being conducted to follow patients with DM1 or DM2 over a 2 year period to study the presence of myotonia, how it's perceived and its impact on patients quality of life. This study will be conducted at 6 study sites located in France.100 Patients will be recruited from the DM Scope Registry only. The study involves two parts. Part 1 will look back up to 18 months of past medical history that is already available from the DM Scope Registry. Part 2 will follow the same patients for 24 months, with study visits at Day 1 (Baseline), 12 months and 24 months. The goal is to better understand how myotonia symptoms and complications such as heart and other systemic problems develop and change over time. A smaller, sub-study will take place at one site, using new exploratory methods in about 40 patients with DM1 who are also part of the Track DM Study.	Myopathies	À vérifier	Traitement symptomatique	France	À vérifier
MexiletineThe purpose of this research study is to find out whether the drug mexiletine will be effective in lowering motor neuron electrical activity in the brains and nerves in the arms of people with ALS. The investigators will also determine if there are any signs that the drug may slow down the progression of ALS and reduce muscle cramps and muscle twitching. This will be determined through transcranial magnetic stimulation (TMS) and threshold tracking nerve conduction studies (TTNCS). In this trial, the participants will be taking either 300mg/day of mexiletine, 600mg/day of mexiletine, or placebo (non-active study drug).	Myopathies	À vérifier	Ralentissement de la progression	France, Germany, United Kingdom	À vérifier
MexiletineThe purpose of this research study is to find out whether the drug mexiletine will be effective in lowering motor neuron electrical activity in the brains and nerves in the arms of people with ALS. The investigators will also determine if there are any signs that the drug may slow down the progression of ALS and reduce muscle cramps and muscle twitching. This will be determined through transcranial magnetic stimulation (TMS) and threshold tracking nerve conduction studies (TTNCS). In this trial, the participants will be taking either 300mg/day of mexiletine, 600mg/day of mexiletine, or placebo (non-active study drug).	Myopathies	Non applicable	Ralentissement de la progression	France	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
Mexiletine	Myopathies	Non applicable	NCT04622553	Open-label Extension Study in Paediatric Patients Who Have Completed the MEX-NM-301 Study.	COMPLETED
Mexiletine	Myopathies	À vérifier	NCT04616807	An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders	COMPLETED
Track-DM — An Ambispective Natural History Study in Myotonic Dystrophy Patients Linking Retrospective Data Captured From the DM-Scope Registry With a Prospective 24-month Follow-up	Myopathies	À vérifier	NCT07732439	Track-DM — An Ambispective Natural History Study in Myotonic Dystrophy Patients Linking Retrospective Data Captured From the DM-Scope Registry With a Prospective 24-month Follow-up Period	NOT_YET_RECRUITING
Mexiletine	Sclérose latérale amyotrophique	Phase 2	NCT02781454	Mexiletine in Sporadic Amyotrophic Lateral Sclerosis	COMPLETED

Publications

6

Molécule	Indication / population	Titre	Journal	Date
Mexiletine		Case Report: Overlap of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia in two Chinese children with -related calmodulinopathy.	Frontiers in pediatrics
Mexiletine		Universal Metal-Free Deborylation-Deuteration via Redox-Decoupled Tandem Flow Electrosynthesis.	Journal of the American Chemical Society
Mexiletine		Expression Defects of SCN5A Common Polymorphisms S524Y and H558R in the Q1077 Splice Variant Can Be Rescued by Mexiletine.	Cells
Mexiletine		Multimodality Risk Stratification in Athletes With Long QT Syndrome.	JACC. Case reports
Mexiletine		An Unusual Genetic Variant of Long QT Syndrome with Late Presentation in the Sixth Decade.	The Journal of innovations in cardiac rhythm management
Mexiletine		Common genetic variants of the cardiac sodium channel alter patient response to class 1b antiarrhythmics.	Journal of precision medicine (Amsterdam, Netherlands)